Real-world symptom improvement in paediatric atopic dermatitis: insights from patient‑reported outcome measures with mometasone furoate
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20262335Keywords:
Real-world symptom , Patient‑reported outcome measures , Atopic dermatitisAbstract
Patient‑reported outcome measures (PROMs) are validated tools that complement physician assessments and play a crucial role in guiding treatment decisions and monitoring disease burden in atopic dermatitis (AD). However, their use in routine clinical practice stays limited due to low physician awareness and adoption1. Additionally, topical corticosteroid (TCS) phobia among patients and caregivers can adversely affect adherence and treatment outcomes.
References
Cherrez-Ojeda I, Bousquet J, Giménez-Arnau A, Godse K, Krasowska. Patient-reported outcome measures in atopic dermatitis and chronic urticaria are underused in clinical practice. J Allerg Clin Immunol Pract. 2024;12(6):1575-83.
Li AW, Yin ES, Antaya RJ. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. JAMA Dermatol. 2017;153(10):1036-42.
Spada F, Barnes TM, Greive KA. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. Australas J Dermatol. 2018;59(3):e168-74.
Barrett A, Hahn-Pedersen J, Kragh N. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults. Patient. 2019;12:445-9.
Downloads
Published
How to Cite
Issue
Section
